Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML (Q66031894)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML |
clinical trial |
Statements
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec) (English)
0 references
July 2005
0 references
September 2006
0 references
724
0 references
18 year
0 references
90 year
0 references